Management of erectile dysfunction in diabetes: An update for 2008

Current Diabetes Reports

Volumn 8, Issue 6, 2008, Pages 437-443

  Price, David ^a   Hackett, Geoffrey ^b  

^a MORRISTON HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INVICORP; MEDA AB; NITRATE; NITRIC OXIDE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TESTOSTERONE; UNCLASSIFIED DRUG; VARDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANDROGEN DEFICIENCY; AUTONOMIC NEUROPATHY; BACKACHE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; FLUSHING; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MUSCLE CRAMP; NON INSULIN DEPENDENT DIABETES MELLITUS; NOSE CONGESTION; OPTIC NERVE DISEASE; OPTIMAL DRUG DOSE; PREVALENCE; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SMOOTH MUSCLE RELAXATION; VACUUM; VASODILATATION; VISUAL DISORDER;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; ERECTILE DYSFUNCTION; HUMANS; MALE; METABOLIC SYNDROME X; PENILE ERECTION;

EID: 63149182905     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0076-0     Document Type: Review

References (43)

1. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, et al.: Prevalence and independent risk factors for erectile dysfunction in Spain: Results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001, 166: 569-574.
2. McCulloch DK, Campbell IW, Wu FC, et al.: The prevalence of diabetic impotence. Diabetologia 1980, 18: 279-283.
3. HackeTt GI: Impotence: the most neglected complication of diabetes. Diabetes Res 1995, 28: 75-83.
4. Sairam K, Kulinskaya E, Boustead GB, et al.: Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU Int 2001, 88: 68-71.
5. Saenz de Tejada I, Angulo J, Cellek S, et al.: Physiology of erectile function. J Sex Med 2004, 1: 254-265.
6. Saenz de Tejada I, Goldstein I, Azadzoi K, et al.: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989, 320: 1025-1030.
7. Angulo J, Cuevas P, Fernandez A, et al.: Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF. Biochem Biophys Res Commun 2003, 312: 1202-1208.
8. Cartledge JJ, Eardley I, Morrison JF: Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001, 87: 402-407.
9. Grimm RH Jr, Flack JM, Grandits GA, et al.: Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996, 275: 1549-1556.
10. Solomon H, Samarasinghe YP, Feher MD, et al.: Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 2006, 60: 141-145.
11. Kapoor D, Malkin CJ, Channer KS, Jones TH: Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005, 63: 239-250.
12. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL: Endogenous sex hormones and the development of type 2 diabetes in older men and women: The Rancho Bernardo study. Diabetes Care 2002, 25: 55-60.
13. Kupelian V, Page ST, Araujo AB, et al.: Low sex hormonebinding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006, 91: 843-850.
14. Ma RC, So WY, Yang X, et al.: Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008, 51: 2045-2050.
15. Gazzaruso C, Solerte SB, Pujia A, et al.: Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: A potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 2008, 51: 2040-2044.
16. Price SE, Gingell JC, Gepi-Attee S, et al.: Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998, 15: 821-825.
17. Jackson G, Montorsi P, Cheitlin MD: Cardiovascular safety of sildenafil citrate (Viagra): An updated perspective. Urology 2006, 68(3 Suppl): 47-60.
18. Muller JE, Mittleman A, Maclure M, et al.: Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA 1996, 275: 1405-1409.
19. Jackson G, Betteridge J, Dean J, et al.: A systematic approach to erectile dysfunction in the cardiovascular patient: A Consensus Statement - update 2002. Int J Clin Pract 2002, 56: 663-671.
20. Pomeranz HD, Bhavsar AR: Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (Viagra): A report of seven new cases. J Neuroophthalmol 2005, 25: 9-13.
21. McGwin G Jr, Vaphiades MS, Hall TA, Owsley C: Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction. Br J Ophthalmol 2006, 90: 154-157.
22. Gorkin L, Hvidsten K, Sobel RE, Siegel R: Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract 2006, 60: 500-503.
23. Dean J, Hackett GI, Gentile V, et al.: Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: Results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006, 3: 650-661.
24. von KA, Rajfer J, Segal S, et al.: A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004, 45: 499-507.
25. Eardley I, Mirone V, Montorsi F, et al.: An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005, 96: 1323-1332.
26. Pegge NC, Twomey AM, Vaughton K, et al.: The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. Diabet Med 2006, 23: 873-878.
27. McCullough AR, Barada JH, Fawzy A, et al.: Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002, 60(2 Suppl 2): 28-38.
28. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV: Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003, 6: 94-99.
29. Greco EA, Spera G, Aversa A: Combining testosterone and PDE5 inhibitors in erectile dysfunction: Basic rationale and clinical evidences. Eur Urol 2006, 50: 940-947.
30. Price DE, Cooksey G, Jehu D, et al.: The management of impotence in diabetic men by vacuum tumescence therapy. Diabet Med 1991, 8: 964-967.
31. Armstrong DK, Convery AG, Dinsmore WW: Reasons for patient drop-out from an intracavernous auto-injection programme for erectile dysfunction. Br J Urol 1994, 74: 99-101.
32. Gerstenberg TC, Metz P, Ottesen B, Fahrenkrug J: Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 1992, 147: 1277-1279.
33. Fulgham PF, Cochran JS, Denman JL, et al.: Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998, 60(6 Pt 1): 2041-2046.
34. Rendell MS, Rajfer J, Wicker PA, Smith MD: Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999, 281: 421-426.
35. Safarinejad MR: Oral sildenafil in the treatment of erectile dysfunction in diabetic men: A randomized double-blind and placebo-controlled study. J Diabetes Complications 2004, 18: 205-210.
36. Stuckey BG, Jadzinsky MN, Murphy LJ, et al.: Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: Results of a randomized controlled trial. Diabetes Care 2003, 26: 279-284.
37. Boulton AJ, Selam JL, Sweeney M, Ziegler D: Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001, 44: 1296-1301.
38. Fonseca V, Seftel A, Denne J, Fredlund P: Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: Analysis of data from tadalafil clinical trials. Diabetologia 2004, 47: 1914-1923.
39. Goldstein I, Young JM, Fischer J, et al.: Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003, 26: 777-783.
40. DeBusk RF, Pepine CJ, Glasser DB, et al.: Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004, 93: 147-153.
41. Carson CC, Rajfer J, Eardley I, et al.: The efficacy and safety of tadalafil: An update. BJU Int 2004, 93: 1276-1281.
42. Brock GB, McMahon CG, Chen KK, et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002, 168(4 Pt 1): 1332-1336.
43. Valiquette L, Young JM, Moncada I, et al.: Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: A randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2005, 80: 1291-1297.